Berry Liam, Neale Quinn, Arora Rajat, Ramirez Danyel, Brizuela Marc, Domalaon Ronald, Arthur Gilbert, Schweizer Frank
Department of Chemistry, University of Manitoba, Winnipeg, MB R3T 2N2, Canada.
Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, MB R3E 3N4, Canada.
Antibiotics (Basel). 2024 Jan 3;13(1):43. doi: 10.3390/antibiotics13010043.
Colistin is primarily used as a last resort antibiotic against highly resistant Gram-negative bacteria (GNB). Rising rates of colistin resistance, however, may limit future use of this agent. The anthelmintic drug niclosamide has been shown to enhance colistin activity in combination therapy, but a detailed structure-activity relationship (SAR) for niclosamide against GNB has yet to be studied. A series of niclosamide analogs were synthesized to perform an SAR, leading to the discovery of a lead compound that displayed comparable colistin-potentiating activity to niclosamide with reduced cytotoxicity. Overall, this work provides important insights into synthetic strategies for the future development of new niclosamide derivatives and demonstrates that toxicity to mammalian cells can be reduced while maintaining colistin potentiation.
黏菌素主要用作对抗高度耐药革兰氏阴性菌(GNB)的最后一道抗生素防线。然而,黏菌素耐药率的上升可能会限制该药物未来的使用。驱虫药氯硝柳胺已被证明在联合治疗中可增强黏菌素的活性,但氯硝柳胺针对GNB的详细构效关系(SAR)尚未得到研究。合成了一系列氯硝柳胺类似物以进行构效关系研究,从而发现了一种先导化合物,其表现出与氯硝柳胺相当的黏菌素增强活性,且细胞毒性降低。总体而言,这项工作为新型氯硝柳胺衍生物的未来开发提供了重要的合成策略见解,并表明在维持黏菌素增强作用的同时可降低对哺乳动物细胞的毒性。